logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Mid 2020
CohBar, Inc.
Activity readout from Phase 1a/1b clinical trial of CB4211
Nonalcoholic steatohepatitis (NASH) and obesity
Mid 2020
La Jolla Pharmaceutical Co
Topline results from a pivotal study of LJPC-401
Beta Thalassemia
Mid 2020
Vascular Biogenics Ltd.
Data readout from phase II study of VB-111
Recurrent glioblastoma multiforme
Mid 2020
Constellation Pharmaceuticals, Inc.
Interim phase II data of CPI-1205 (ProSTAR)
Metastatic castration-resistant prostate cancer (mCRPC)
Mid 2020
ChemoCentryx Inc.
Top-line data from phase IIb clinical trial of Avacopan (AURORA)
Hidradenitis Suppurativa
Mid 2020
Denali Therapeutics Inc.
Data readout from phase Ib clinical study of DNL747
Amyotrophic lateral sclerosis
Mid 2020
Denali Therapeutics Inc.
Data readout from phase Ib clinical study of DNL747
Alzheimer's disease
Mid 2020
scPharmaceuticals Inc.
Refiling of NDA for Furoscix
Heart failure
Mid 2020
Ovid Therapeutics Inc.
Top-line data from pivotal phase III trial of OV101 (NEPTUNE)
Angelman Syndrome
Mid 2020
Akebia Therapeutics, Inc.
Top-line results from phase III program of Vadadustat (PRO2TECT)
non-dialysis dependent CKD subjects with anemia due to CKD
Mid 2020
Cyclerion Therapeutics, Inc.
Data readout from phase II study of Olinciguat (STRONG SCD)
Sickle cell disease
Mid 2020
4SC AG
VSE.F
Top-line results from pivotal phase II study of Resminostat
Cutaneous T cell lymphoma
Mid 2020
Fulcrum Therapeutics
Submission of IND for FTX-6058
Sickle cell disease
Mid 2020
Fulcrum Therapeutics
Submission of IND for FTX-6058
ß-Thalassemia
Mid 2020
RAPT Therapeutics, Inc.
Results from phase Ib portion of phase 1 clinical trial of RPT193
Atopic dermatitis
Mid 2020
CASSAVA SCIENCES INC
Top-line results from phase 2b study of PTI-125
Alzheimer's disease
Mid 2020
Dicerna Pharmaceuticals, Inc.
Proof-of-concept data from all planned cohorts of DCR-HBVS Phase 1 clinical trial
Chronic hepatitis B virus (HBV) infection
Mid 2020
BioXcel Therapeutics, Inc.
Topline results from Phase 3 study of BXCL501
Acute treatment of agitation in patients with schizophrenia
Mid 2020
BioXcel Therapeutics, Inc.
Topline results from Phase 3 study of BXCL501
Acute treatment of agitation in patients with bipolar disorder
Mid 2020
Arcus Biosciences, Inc
Initial data from Phase 1b expansion trial of AB928
Multiple tumor types
Mid 2020
Arcus Biosciences, Inc
Early data from phase Ib expansion trial of AB680
PDAC
Mid 2020
Forty Seven, Inc.
Updated data from phase Ib trial evaluating Magrolimab in combination with Azacitidine
Myelodysplastic syndrome and acute myeloid leukemia
Mid 2020
ANAVEX LIFE SCIENCES CORP.
Data from phase II study of ANAVEX2-73
Parkinson's disease dementia
Q2 2020
Biohaven Pharmaceutical Holding Co Ltd.
Topline data from Phase 2/3 trial of Troriluzole adjunctive therapy
Obsessive Compulsive Disorder
Q2 2020
Momenta Pharmaceuticals Inc
Additional data from Part B of phase I/II clinical trial of M254
Idiopathic thrombocytopenic purpura (ITP)
>